Tyra Biosciences Inc.
15.96
0.86 (5.70%)
At close: Jan 14, 2025, 3:59 PM
15.94
-0.13%
After-hours Jan 14, 2025, 04:00 PM EST
undefined%
Bid 11.5
Market Cap 843.83M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -1.61
PE Ratio (ttm) -9.91
Forward PE n/a
Analyst Buy
Ask 17.2
Volume 608,508
Avg. Volume (20D) 357,172
Open 15.24
Previous Close 15.10
Day's Range 15.11 - 16.57
52-Week Range 12.17 - 29.60
Beta undefined

About TYRA

Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondro...

Industry Biotechnology
Sector Healthcare
IPO Date Sep 15, 2021
Employees 49
Stock Exchange NASDAQ
Ticker Symbol TYRA

Analyst Forecast

According to 6 analyst ratings, the average rating for TYRA stock is "Buy." The 12-month stock price forecast is $30.5, which is an increase of 91.10% from the latest price.

Buy 100.00%
Hold 0.00%
Sell 0.00%
Stock Forecasts
2 months ago · Source
-23.35%
Tyra Biosciences shares are trading lower. The com... Unlock content with Pro Subscription
11 months ago · Source
+29.29%
Tyra Biosciences shares are trading higher after the company announced $200 million in private placement financing.